Belite Bio (BLTE) EBITDA (2022 - 2026)

Belite Bio's EBITDA history runs 5 years deep, the most recent figure standing at -$32.7 million for Q1 2026.

• On a quarterly basis, EBITDA rose 100.0% year-over-year to -$32.7 million in Q1 2026; TTM through Mar 2026 was -$17.6 billion, a 99.89% increase from a year earlier, with the FY2025 full-year figure at -$84.2 million, down 110.54% from the prior year.
• EBITDA retreated to -$32.7 million in Q1 2026 per BLTE's latest filing, from -$28077.0 in the prior quarter.
• Across five years, EBITDA topped out at -$9740.0 in Q3 2024 and bottomed at -$15517.0 billion in Q1 2025.
• The 5-year median for EBITDA is -$1.3 billion (2022), against an average of -$973.3 billion.
• Across the five-year window, EBITDA tumbled 186223.25% in 2025 and surged 100.0% in 2026, its largest moves.
• Year by year, EBITDA stood at -$6.7 million in 2022, then declined by 3.48% to -$7.0 million in 2023, then jumped by 99.84% to -$11457.0 in 2024, then slumped by 145.06% to -$28077.0 in 2025, then plunged by 116308.45% to -$32.7 million in 2026.
• Per Business Quant, the three latest BLTE EBITDA figures stand at -$32.7 million (Q1 2026), -$28077.0 (Q4 2025), and -$23018.0 (Q3 2025).